MASLD and MASH: Steatotic liver disease joins the deadly quartet
Metabolic dysfunction-associated steatotic liver disease (MASLD) is linked to insulin resistance and cardiometabolic disorders. This review synthesizes current information on the epidemiology, pathophysiology, and treatment of MASLD and its progressive form, metabolic dysfunction- associated steatohepatitis (MASH), underscoring how to integrate established metabolic care with emerging treatments to address the growing MASLD burden.
Authors
- Risheng Xu (ORCID: https://orcid.org/0000-0003-4288-1232)
- N. Abate
- Richard Su
- Rise Stribling
Institutions
- Baylor College of Medicine (US)
- TomoWave Laboratories (United States) (US)
Publication Details
- Journal
- Cleveland Clinic Journal of Medicine
- Published
- 2026-09-01
- DOI
- https://doi.org/10.3949/ccjm.93a.25117
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00